Schellhammer Urological Research Foundation
Today's Research Offers Tomorrow's Hope
Welcome Clinicians
About Us
Patient Information
Areas of Urology and Research


Endoscopic treatment of upper tract transitional cell carcinoma.
Soderdahl DW, Fabrizio MD, Rahman NU, Jarrett TW, Bagley DH.
Urol Oncol. 2005 Mar-Apr;23(2):114-22.

Overexpression of alpha-defensin is associated with bladder cancer invasiveness.
Holterman DA, Diaz JI, Blackmore PF, Davis JW, Schellhammer PF, Corica A, Semmes OJ, Vlahou A.
Urol Oncol. 2006 Mar-Apr;24(2):97-108.

A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study.
Sarosdy MF, Tangen CM, Weiss GR, Nestok BR, Benson MC, Schellhammer PF, Sagalowsky AI, Wood DP Jr, Crawford ED.
Urol Oncol. 2005 Nov-Dec;23(6):386-9.

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF.
J Urol. 2007 Dec;178(6):2314-30.


Clinical and consumer trial performance of a sensitive immunodiagnostic home test that qualitatively detects low concentrations of sperm following vasectomy.
Klotz KL, Coppola MA, Labrecque M, Brugh VM 3rd, Ramsey K, Kim KA, Conaway MR, Howards SS, Flickinger CJ, Herr JC.
J Urol. 2008 Dec;180(6):2569-76.

Herniorrhaphy with polypropylene mesh causing inguinal vasal obstruction: a preventable cause of obstructive azoospermia.
Shin D, Lipshultz LI, Goldstein M, Barmé GA, Fuchs EF, Nagler HM, McCallum SW, Niederberger CS, Schoor RA, Brugh VM 3rd, Honig SC.
Ann Surg. 2005 Apr;241(4):553-8.

Isolation and enrichment of murine spermatogonial stem cells using rhodamine 123 mitochondrial dye.
Lo KC, Brugh VM 3rd, Parker M, Lamb DJ.
Biol Reprod. 2005 Mar;72(3):767-71.


Single center experience with percutaneous and laparoscopic cryoablation of small renal masses.
Malcolm JB, Berry TT, Williams MB, Logan JE, Given RW, Lance RS, Barone B, Shaves S, Vingan H, Fabrizio MD.
J Endourol. 2009 Jun;23(6):907-11.

Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ, Belldegrun AS.
Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):894-900. Epub 2009 Feb 24.

Partial nephrectomy: a contemporary review regarding outcomes and different techniques.
Riggs SB, Larochelle JC, Belldegrun AS.
Cancer J. 2008 Sep-Oct;14(5):302-7.

Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB, Pantuck AJ.
Cancer. 2008 Nov 1;113(9):2457-63.

Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival.
Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Pantuck AJ, Belldegrun AS.
Cancer. 2008 Oct 1;113(7):1641-8.

Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
Shuch B, La Rochelle JC, Wu J, Klatte T, Riggs SB, Kabbinavar F, Belldegrun AS, Pantuck AJ.
Cancer. 2008 Sep 15;113(6):1324-31.

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS.
BJU Int. 2008 Sep;102(6):692-6. Epub 2008 Apr 10.

Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas.
Klatte T, Patard JJ, de Martino M, Bensalah K, Verhoest G, de la Taille A, Abbou CC, Allhoff EP, Carrieri G, Riggs SB, Kabbinavar FF, Belldegrun AS, Pantuck AJ.
J Urol. 2008 May;179(5):1719-26.

Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS.
Clin Cancer Res. 2007 Dec 15;13(24):7388-93.

Update on partial nephrectomy and novel techniques.
Riggs SB, Klatte T, Belldegrun AS.
Urol Oncol. 2007 Nov-Dec;25(6):520-2.

The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma.
Klatte T, Seligson DB, Leppert JT, Riggs SB, Yu H, Zomorodian N, Kabbinavar FF, Strieter RM, Belldegrun AS, Pantuck AJ.
J Urol. 2008 Jan;179(1):61-6. Epub 2007 Nov 13.

Prognostic factors for renal cell carcinoma with tumor thrombus extension.
Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS.
J Urol. 2007 Oct;178(4 Pt 1):1189-95; discussion 1195.


Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis.
Singh AM, Gagnon G, Collins B, Niroomand-Rad A, McRae D, Zhang Y, Regan J, Lynch J, Dritschilo A.
Prostate. 2005 Jan 1;62(1):54-60.

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N
Cancer. 2009 Jun 17.

High-grade prostate cancer and the prostate cancer prevention trial.
Logothetis CJ, Schellhammer PF.
Cancer Prev Res (Phila Pa). 2008 Aug;1(3):151-2.

Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids.
White KY, Rodemich L, Nyalwidhe JO, Comunale MA, Clements MA, Lance RS, Schellhammer PF, Mehta AS, Semmes OJ, Drake RR.
J Proteome Res. 2009 Feb;8(2):620-30.

Practical system of assessment: an updated acronym for PSA.
Schellhammer PF.
J Urol. 2007 Jan;177(1):14-5.

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM.
J Clin Oncol. 2006 Jul 1;24(19):3089-94.

Timing of androgen deprivation therapy: some questions answered, others not.
Schellhammer PF.
J Natl Cancer Inst. 2006 Jun 21;98(12):802-3.

Re: Editorial comment on Laparoscopic radical prostatectomy: is intact organ removal attainable? Study of margin status.
Schellhammer PF.
J Urol. 2006 May;175(5):1963; author reply 1964.

Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer.
Schellhammer PF, Hershberg RM.
World J Urol. 2005 Feb;23(1):47-9. Epub 2005 Jan 13.

Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
Hubosky SG, Fabrizio MD, Schellhammer PF, Barone BB, Tepera CM, Given RW.
J Endourol. 2007 Dec;21(12):1521-31.

Postoperative robotic telerounding: a multicenter randomized assessment of patient outcomes and satisfaction.
Ellison LM, Nguyen M, Fabrizio MD, Soh A, Permpongkosol S, Kavoussi LR.
Arch Surg. 2007 Dec;142(12):1177-81; discussion 1181.

Computer modeling technology to assess extracapsular tissue coverage of whole mount sections after retropubic and laparoscopic radical prostatectomy.
Schellhammer PF, Diaz JI, Fabrizio MD, Davis JW, Given RW, Main B, Chaganty NR, Hussein R, McKenzie R.
J Urol. 2007 Oct;178(4 Pt 1):1301-5.

Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution.
Ball AJ, Gambill B, Fabrizio MD, Davis JW, Given RW, Lynch DF, Shaves M, Schellhammer PF.
J Endourol. 2006 Oct;20(10):723-31.

Laparoscopic radical prostatectomy: evaluation of specimen pathologic features to critically assess and modify surgical technique.
Soderdahl DW, Diaz JI, Rabah DM, Schellhammer PF, Fabrizio MD.
Urology. 2005 Sep;66(3):552-6.

Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized prostate cancer.
Soderdahl DW, Davis JW, Schellhammer PF, Given RW, Lynch DF, Shaves M, Burke BL, Fabrizio MD.
J Endourol. 2005 Apr;19(3):318-26.

Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
Polascik TJ, Given RW, Metzger C, Julian SR, Vestal JC, Karlin GS, Barkley CS, Bilhartz DL, McWhorter LT, Lacerna LV.
Urology. 2005 Nov;66(5):1054-9.

Modified running vesicourethral anastomosis after robotically assisted laparoscopic radical prostatectomy: use of solitary Lapra-Ty to secure posterior approximation.
Ball AJ, Bordeau KP, Davis JW, Given RW, Lynch DF, Fabrizio MD.
Urology. 2005 Jul;66(1):16-8.

Clinical Collection and Protein Properties of Expressed Prostatic Secretions as a Source for Biomarkers of Prostatic Disease.
Drake RR, White KY, Fuller TW, Igwe E, Clements MA,Nyalwidhe JO, Given RW, Lance RS, Semmes OJ.
J Proteomics. 2009 Jan 19.


Peyronie's disease: update on medical management and surgical tips.
Jordan GH.
Can J Urol. 2007 Dec;14 Suppl 1:69-74. Review.

The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study.
Jordan GH.
J Sex Med. 2008 Jan;5(1):180-7.

The use of collagenase in the treatment of Peyronie's disease M.K. Gelbard, A. Lindner, and J.J. Kaufman.
Glina S, Gelbard MK, Akkus E, Jordan GH, Levine LA.
J Sex Med. 2007 Sep;4(5):1209-13.

Management of recurrent anastomotic stenosis following radical prostatectomy using holmium laser and steroid injection.
Eltahawy E, Gur U, Virasoro R, Schlossberg SM, Jordan GH.
BJU Int. 2008 Sep;102(7):796-8. Epub 2008 Jul 30.

Vessel-sparing excision and primary anastomosis (for proximal bulbar urethral strictures).
Gur U, Jordan GH.
BJU Int. 2008 May;101(9):1183-95.

Long-term follow-up for reconstruction of strictures of the fossa navicularis with a single technique.
Virasoro R, Eltahawy EA, Jordan GH.
BJU Int. 2007 Nov;100(5):1143-5.

Long-term followup for excision and primary anastomosis for anterior urethral strictures.
Eltahawy EA, Virasoro R, Schlossberg SM, McCammon KA, Jordan GH.
J Urol. 2007 May;177(5):1803-6.

The technique of vessel sparing excision and primary anastomosis for proximal bulbous urethral reconstruction.
Jordan GH, Eltahawy EA, Virasoro R.
J Urol. 2007 May;177(5):1799-802.

Jordan GH.
J Urol. 2007 Jan;177(1):16.

Reconstruction and management of posterior urethral and straddle injuries of the urethra.
Jordan GH, Virasoro R, Eltahawy EA.
Urol Clin North Am. 2006 Feb;33(1):97-109, vii.

Primary urethral reconstruction: the cost minimized approach to the bulbous urethral stricture.
Rourke KF, Jordan GH.
J Urol. 2005 Apr;173(4):1206-10.


Hounsfield unit density accurately predicts ESWL success.
Magnuson WJ, Tomera KM, Lance RS.
Alaska Med. 2005 Jul-Sep;47(2):6-9.

Urodynamic Changes and Initial Results of the AdVance Male Sling.
Davies TO, Bepple JL, McCammon KA.
Urology. 2009 May 8. [Epub ahead of print]

Usefulness of adrenal vein sampling in the evaluation of aldosteronism.
Schwab CW 2nd, Vingan H, Fabrizio MD.
J Endourol. 2008 Jun;22(6):1247-50.